PurMinds Partners With SpectroChip and Taiwan Hospital on Diagnostic Testing
PurMinds Enterprises, Inc. (OTC:PFSF) has signed a five-year collaboration framework agreement with SpectroChip Inc. and Taiwan-based Kaohsiung Municipal Siaogang Hospital. The partnership aims to support research, teaching, and clinical validation of point-of-care diagnostic solutions, including plans to establish a joint clinical validation testing center.
The alliance combines SpectroChip photonic chip technology with the PurMinds SwiftLab Platform, which uses a miniaturized spectrometer in a portable reader designed to provide quantitative testing results in five minutes or less. As part of the framework, SpectroChip will provide Siaogang Hospital with 3 million NT dollars (about 94,000 USD) in research and educational funding over five years.
Moving forward, individual research projects under the framework will require separate written contracts detailing scope, funding, and deliverables. Institutional review board approval and ethical review will be necessary for human studies, while PurMinds continues seeking market regulatory clearances, as its reader and cassettes currently lack approval from the US Food and Drug Administration and Health Canada.
Key points
- PurMinds Enterprises, Inc. (OTC:PFSF), SpectroChip, and Kaohsiung Municipal Siaogang Hospital formed a five-year diagnostic research collaboration.
- The alliance plans to establish a joint testing center focused on evaluating portable photonic-chip diagnostic technology.
- SpectroChip committed 3 million NT dollars (around 94,000 USD) in research and educational funding over five years.
- PurMinds SwiftLab Platform devices currently lack regulatory clearance for clinical use in the United States and Canada.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the agreement between PurMinds, SpectroChip, and Siaogang Hospital?
The three organizations signed a five-year collaboration framework to conduct research, teaching, and clinical validation of point-of-care photonic diagnostic tools, planning to establish a joint testing center.
What funding is included in the PurMinds diagnostic collaboration?
SpectroChip is contributing 3 million NT dollars (approximately 94,000 USD) over five years to support teaching, testing, equipment maintenance, and research personnel at Siaogang Hospital.
Are PurMinds SwiftLab diagnostic readers approved by the FDA?
No, the SpectroCision reader and PurMinds cassettes have not been cleared or approved by the US FDA or Health Canada and are not available for clinical use in either country.